Why the study?
Does rapid infusion Rituximab added to chemotherapy cause clinical cardiac toxicity in patients with non-Hodgkin lymphoma?
Does rapid infusion Rituximab added to chemotherapy cause clinical cardiac toxicity in patients with non-Hodgkin lymphoma?
Rapid infusion Rituximab added to chemotherapy in non-Hodgkin lymphoma patients does not cause clinical congestive heart failure, though asymptomatic LVEF drops >15% may not fully recover.
No clinical HF observed with rapid rituximab; leaves open whether asymptomatic LVEF declines require prospective monitoring in lymphoma.
Background. Prospective study based on measuring the left ventricular ejection function (LVEF) of lymphoma patients treated with rapid infusion Rituximab (one hour). Patients and Methods. 42 patients with non-Hodgkin lymphoma were treated with rapid infusion Rituximab-based chemotherapy (mostly CHOP-R). Basal LVEF was measured before chemotherapy and every six months after treatment. Results. An average of 6.5 infusions per patient were administered (total of 273 infusions). Twenty-four (57%) patients had at least one cardiovascular risk factor. In 13 patients (31%) we observed a decreased in the post-treatment LVEF of over 10%. Patients (3) with drop > 10% recovered normally, but when LVEF decreased by over 15% (6 patients), no one recovered until normal level. None of them developed clinical congestive failure. Conclusion. Rapid infusion Rituximab added to chemotherapy does not cause clinical cardiac toxicity. Patients recover LVEF when it decreased less than 15%.
No takes yet. Share an insight, caveat, or question.
Provencio et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: